Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 7/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 4/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL70370 | 0.98 | CYP4F2 (0.68) | CYP4F2CYP4A11MAOBTAAR1BCHE | |
| SCHEMBL2206195 | 0.90 | CYP4F2 (0.66) | CYP4F2CYP4A11MAOBBCHEMGLL | |
| SCHEMBL2655137 | 0.88 | CYP4F2 (0.64) | CYP4F2CYP4A11MAOBBCHEMGLL | |
| SCHEMBL30207536 | 0.85 | MAOB (0.70) | CYP4F2CYP4A11MAOBBCHEMAOA | |
| SCHEMBL538599 | 0.85 | MAOB (0.70) | CYP4F2CYP4A11MAOBBCHEMAOA | |
| SCHEMBL7349864 | 0.84 | MAOB (0.64) | CYP4F2CYP4A11MAOBTAAR1 | |
| Hydrochloric Acid SCHEMBL538603 | 0.84 | MAOB (0.73) | CYP4F2CYP4A11MAOBBCHEMAOA | |
| SCHEMBL69512 | 0.83 | MAOB (0.78) | MAOBTAAR1MAOA | |
| Hydrochloric Acid SCHEMBL2568656 | 0.83 | MAOB (0.65) | MAOBTAAR1 | |
| SCHEMBL15761340 | 0.83 | BCHE (0.70) | CYP4F2CYP4A11MAOBBCHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-110343068-B | 2-amino-2-quinolyl ethanol beta 2-receptor agonist and preparation method and application thereof | 沈阳药科大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-107531703-B | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| EP-2318126-B1 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | UNIV TEXAS (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3286191-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| US-5120853-A | Reacting optically active amine-boron complex with oxime or ketone to produce opotically active amine or alcohol compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-09 | — | — | US | disclosed |
| US-5011989-A | Asymmetric reducing agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0422328-A2 | Substituted isoquinolines and their use | Euro-Celtique S.A. (LU) | 1991-04-17 | — | — | EP | disclosed |
| US-4968698-A | FUNGICIDES, ANTIPROTOZOA AGENTS | BURROUGHS WELLCOME CO. (US) | 1990-11-06 | — | — | US | disclosed |
| US-4956371-A | PLATELET ACTIVATING FACTOR | EUROCELTIQUE, S.A. (LU) | 1990-09-11 | — | — | US | disclosed |
| US-4868296-A | 6-(1-carbamoyl-1-hydroxymethyl) penicillanic acid derivatives | PFIZER INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0170524-A2 | Nitrogen containing heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
| EP-0028959-B1 | 5,8,13,13A-TETRAHYDRO-6H-DIBENZO(A,G)QUINOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | U.R.P.H.A. (FR) | 1985-01-30 | — | — | EP | disclosed |
| EP-0028959-A1 | 5,8,13,13a-Tetrahydro-6H-dibenzo(a,g)quinolizine derivatives, process for their preparation and pharmaceutical compositions containing them | U.R.P.H.A. (FR) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | CYP4F2 451/4885CYP4A11 168/4885MAOB 1008/4885 |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | CYP4F2 2041/4885CYP4A11 1393/4885MAOB 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.